SCHEMBL4964402

SCHEMBL4964402

O=C(Cl)OOCCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
TDP1 Q9NUW8 3/20 0.48
HCAR2 Q8TDS4 1/20 0.46
KEAP1 Q14145 1/20 0.45
FFAR1 O14842 2/20 0.45
ESR1 P03372 1/20 0.45
ESR2 Q92731 1/20 0.45
LMNA P02545 1/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPK1 P28482 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
GLA P06280 1/20 0.44
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HIF1A Q16665 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20397947 0.82 TDP1 (0.50) ALDH1A1TDP1HCAR2KEAP1FFAR1
SCHEMBL9763370 0.81 ALDH1A1 (0.52) ALDH1A1TDP1HCAR2KEAP1FFAR1
SCHEMBL4644782 0.80 ALDH1A1 (0.55) ALDH1A1TDP1LMNANPC1RAB9A
SCHEMBL3845851 0.80 ALDH1A1 (0.64) ALDH1A1TDP1HCAR2KEAP1FFAR1
SCHEMBL335181 0.80 ALDH1A1 (0.64) ALDH1A1TDP1HCAR2LMNANPC1
SCHEMBL383730 0.79 LMNA (0.57) ALDH1A1TDP1HCAR2KEAP1FFAR1
SCHEMBL233782 0.77 THRB (0.50) ALDH1A1TDP1HCAR2KEAP1FFAR1
SCHEMBL2706957 0.77 ESR1 (0.45) ALDH1A1TDP1HCAR2KEAP1FFAR1
SCHEMBL6341147 0.76 ALDH1A1 (0.52) ALDH1A1TDP1HCAR2NPC1RAB9A
Bicarbonate SCHEMBL28009994 0.76 TDP1 (0.52) ALDH1A1TDP1HCAR2KEAP1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1282604-B1 SUBSTITUTED CAPROLACTAM CARBONATES AND ETHERS AND THEIR USE AS ANTI-TUMOR AGENTS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-6599898-B2 Selected from the group consisting of breast, lung, non-small cell lung, osteolytic, colon and prostate NOVARTIS AG (CH) 2003-07-29 US disclosed
US-20030055041-A1 Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors KINDER FREDERICK RAY (US) 2003-03-20 US disclosed
EP-1282604-A1 SUBSTITUTED CAPROLACTAM CARBONATES AND ETHERS AND THEIR USE AS ANTI-TUMOR AGENTS Novartis AG (CH) 2003-02-12 EP disclosed
US-6413954-B1 3,4,5-TRIHYDROXY-2-METHOXY-8,8-DIMETHYL-N-((3,6)-HEXAHYDRO-2 -OXO-6-(((DECYLOXY)CARBONYL)OXY)-2H-AZEPIN-3-YL)NON-6-ENON-AMIDES; SYNTHESIS BY ACYLATION AND HYDROLYSIS; HIGHER SELECTIVITY IN KILLING CANCER CELLS; CHEMOTHERAPY NOVARTIS AG (CH) 2002-07-02 US disclosed
WO-2001085697-A1 SUBSTITUTED CAPROLACTAM CARBONATES AND ETHERS AND THEIR USE AS ANTI-TUMOR AGENTS NOVARTIS AG (CH) 2001-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055041-A1 Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors VHL, CAPRIN1, CAPN9 ALDH1A1 3668/4885TDP1 4193/4885HCAR2 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.